Screener
Nektar Therapeutics NKTR Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Nektar Therapeutics’s 10-Q, filed May 8, 2026.
- Filed
- May 7, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-212596
| Line item | Three Months Ended March 31, | Three Months Ended March 31, | Three Months Ended March 31, |
|---|---|---|---|
| Total non-operating income (expense), net | (4,036) | (1,834) | |
| Loss before provision for income taxes and equity method investment | (43,090) | (46,369) | |
| Provision for income taxes | 64 | 52 | |
| Loss before equity method investment | (43,154) | (46,421) | |
| Loss from equity method investment | (1,750) | (4,461) | |
| Net loss | $ | $$(44,904) | (50,882) |
| Basic and diluted net loss per share | $ | $$(1.82) | (3.62) |
| Weighted average shares outstanding used in computing basic and diluted net loss per share | 24,736,066 | 14,063,402 |
Item 1. Condensed Consolidated Financial Statements—Unaudited:
FAQ
- What is Nektar Therapeutics's net income?
- Nektar Therapeutics (NKTR) reported net income of -$44.9M in Q1 2026.
- How has Nektar Therapeutics's net income changed year-over-year?
- Nektar Therapeutics's net income increased by 11.7% year-over-year, from -$50.88M to -$44.9M.
- What is the long-term trend for Nektar Therapeutics's net income?
- Over 4 years (2021 to 2025), Nektar Therapeutics's net income has grown at a -25.2% compound annual growth rate (CAGR), from -$523.84M to -$164.08M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Nektar Therapeutics's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude